We are a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases through in-silico drug discovery.
We identify targets known to be fundamental drivers of pathology in high prevalent human diseases and which have proven difficult for other drug makers to tackle. Our targets play causal roles in diseases of immunology, oncology, and metabolism, therapies with efficacious small molecules have the potential to transform patient's lives.
We apply leading-edge computational chemistry in conjunction with other technology to harness protein structure data to drug targets and modulate their functional activity
Renthera's computational workflows, enhance structure refinement, ligand placement, and binding analysis to unlock an array of protein targets for structure-based design.
We leverage our brilliant team and the Gödel platform to focus on target's active and allosteric sites designing small molecule modulator with the desired binding mode, functional activity and selectivity.
Our comprehensive expertise spans protein science, biophysics, enzymology and screening. This assures optimization of our therapeutic candidates across a stringent set of drug-like properties.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.